NASDAQ:IDRA

Idera Pharmaceuticals Competitors

$1.02
0.00 (0.00 %)
(As of 04/20/2021 05:18 PM ET)
Add
Compare
Today's Range
$1.00
Now: $1.02
$1.05
50-Day Range
$1.08
MA: $2.65
$5.21
52-Week Range
$1.00
Now: $1.02
$6.14
Volume2.13 million shs
Average Volume2.71 million shs
Market Capitalization$43.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4

Competitors

Idera Pharmaceuticals (NASDAQ:IDRA) Vs. TARA, INMB, AXLA, VYGR, FENC, and AGTC

Should you be buying IDRA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Idera Pharmaceuticals, including Protara Therapeutics (TARA), INmune Bio (INMB), Axcella Health (AXLA), Voyager Therapeutics (VYGR), Fennec Pharmaceuticals (FENC), and Applied Genetic Technologies (AGTC).

Protara Therapeutics (NASDAQ:TARA) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Protara Therapeutics and Idera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protara Therapeutics00303.00
Idera Pharmaceuticals05002.00

Protara Therapeutics currently has a consensus target price of $47.6667, suggesting a potential upside of 221.85%. Idera Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 292.16%. Given Idera Pharmaceuticals' higher possible upside, analysts plainly believe Idera Pharmaceuticals is more favorable than Protara Therapeutics.

Insider and Institutional Ownership

83.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of Idera Pharmaceuticals shares are owned by institutional investors. 45.7% of Protara Therapeutics shares are owned by insiders. Comparatively, 3.5% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Protara Therapeutics and Idera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65

Protara Therapeutics has higher earnings, but lower revenue than Idera Pharmaceuticals.

Risk and Volatility

Protara Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Profitability

This table compares Protara Therapeutics and Idera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protara TherapeuticsN/A-45.45%-41.09%
Idera PharmaceuticalsN/A-771.38%-34.32%

Summary

Protara Therapeutics beats Idera Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for INmune Bio and Idera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00403.00
Idera Pharmaceuticals05002.00

INmune Bio currently has a consensus target price of $19.25, suggesting a potential upside of 74.68%. Idera Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 292.16%. Given Idera Pharmaceuticals' higher possible upside, analysts plainly believe Idera Pharmaceuticals is more favorable than INmune Bio.

Risk and Volatility

INmune Bio has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Earnings & Valuation

This table compares INmune Bio and Idera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-14.69
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65

INmune Bio has higher earnings, but lower revenue than Idera Pharmaceuticals. INmune Bio is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.4% of INmune Bio shares are owned by institutional investors. Comparatively, 25.1% of Idera Pharmaceuticals shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Comparatively, 3.5% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares INmune Bio and Idera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
Idera PharmaceuticalsN/A-771.38%-34.32%

Summary

INmune Bio beats Idera Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Axcella Health (NASDAQ:AXLA) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Axcella Health and Idera Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axcella Health01802.89
Idera Pharmaceuticals05002.00

Axcella Health currently has a consensus target price of $16.1250, suggesting a potential upside of 281.21%. Idera Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 292.16%. Given Idera Pharmaceuticals' higher possible upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Axcella Health.

Volatility and Risk

Axcella Health has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Valuation & Earnings

This table compares Axcella Health and Idera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.20
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65

Idera Pharmaceuticals has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. Comparatively, 25.1% of Idera Pharmaceuticals shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by insiders. Comparatively, 3.5% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Axcella Health and Idera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axcella HealthN/A-79.03%-54.77%
Idera PharmaceuticalsN/A-771.38%-34.32%

Summary

Idera Pharmaceuticals beats Axcella Health on 7 of the 12 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Voyager Therapeutics and Idera Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics08402.33
Idera Pharmaceuticals05002.00

Voyager Therapeutics currently has a consensus target price of $12.1364, suggesting a potential upside of 159.88%. Idera Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 292.16%. Given Idera Pharmaceuticals' higher possible upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Voyager Therapeutics.

Volatility and Risk

Voyager Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Valuation & Earnings

This table compares Voyager Therapeutics and Idera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million1.68$-43,600,000.00($1.21)-3.86
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65

Voyager Therapeutics has higher revenue and earnings than Idera Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of Idera Pharmaceuticals shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by insiders. Comparatively, 3.5% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Voyager Therapeutics and Idera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
Idera PharmaceuticalsN/A-771.38%-34.32%

Summary

Voyager Therapeutics beats Idera Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Idera Pharmaceuticals (NASDAQ:IDRA) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Earnings & Valuation

This table compares Idera Pharmaceuticals and Fennec Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-9.72

Fennec Pharmaceuticals has lower revenue, but higher earnings than Idera Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Idera Pharmaceuticals and Fennec Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Idera Pharmaceuticals05002.00
Fennec Pharmaceuticals00403.00

Idera Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 292.16%. Fennec Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 125.08%. Given Idera Pharmaceuticals' higher possible upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Fennec Pharmaceuticals.

Volatility & Risk

Idera Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Profitability

This table compares Idera Pharmaceuticals and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Idera PharmaceuticalsN/A-771.38%-34.32%
Fennec PharmaceuticalsN/A-84.34%-75.51%

Insider & Institutional Ownership

25.1% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 53.6% of Fennec Pharmaceuticals shares are held by institutional investors. 3.5% of Idera Pharmaceuticals shares are held by company insiders. Comparatively, 9.1% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fennec Pharmaceuticals beats Idera Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Idera Pharmaceuticals (NASDAQ:IDRA) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Earnings & Valuation

This table compares Idera Pharmaceuticals and Applied Genetic Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Idera Pharmaceuticals$1.45 million29.73$-56,510,000.00($1.57)-0.65
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67

Applied Genetic Technologies has higher revenue and earnings than Idera Pharmaceuticals. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Idera Pharmaceuticals and Applied Genetic Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Idera Pharmaceuticals05002.00
Applied Genetic Technologies00603.00

Idera Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 292.16%. Applied Genetic Technologies has a consensus price target of $17.5833, suggesting a potential upside of 385.73%. Given Applied Genetic Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Applied Genetic Technologies is more favorable than Idera Pharmaceuticals.

Volatility & Risk

Idera Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500.

Profitability

This table compares Idera Pharmaceuticals and Applied Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Idera PharmaceuticalsN/A-771.38%-34.32%
Applied Genetic TechnologiesN/A-73.06%-53.25%

Insider & Institutional Ownership

25.1% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 57.9% of Applied Genetic Technologies shares are held by institutional investors. 3.5% of Idera Pharmaceuticals shares are held by company insiders. Comparatively, 7.5% of Applied Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Applied Genetic Technologies beats Idera Pharmaceuticals on 9 of the 13 factors compared between the two stocks.


Idera Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.79flat$171.80 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
INmune Bio logo
INMB
INmune Bio
1.5$11.02flat$169.79 millionN/A-11.36
Axcella Health logo
AXLA
Axcella Health
1.6$4.25flat$169.61 millionN/A-1.98
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.67flat$168.31 million$104.39 million-2.85Analyst Report
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.22flat$162.78 millionN/A-7.59Analyst Report
News Coverage
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.62flat$162.46 million$2.45 million-1.70
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.00flat$161.67 millionN/A-2.81
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.26flat$152.12 millionN/A-1.85News Coverage
Gap Down
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.20flat$147.69 million$32.12 million-86.15
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.50flat$138.29 million$2.33 million0.00News Coverage
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.12flat$134.46 millionN/A0.00News Coverage
Dyadic International logo
DYAI
Dyadic International
1.3$4.74flat$133.64 million$1.68 million-13.94
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.99flat$132.73 millionN/A0.00
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.26flat$130.13 million$20,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$7.08flat$117.80 million$3 million-2.28
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.16flat$112.39 millionN/A-1.49
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.85flat$111.91 million$23.05 million-1.71
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.11flat$111.09 millionN/A-2.96Upcoming Earnings
PolarityTE logo
PTE
PolarityTE
1.4$0.86flat$107.06 million$5.65 million-0.52Increase in Short Interest
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.00flat$97.56 million$140,000.000.00
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.03flat$97.53 million$20.92 million-1.17
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$8.70flat$64.53 millionN/A0.00
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.08flat$63.20 millionN/A-0.86
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.66flat$60.20 million$420,000.00-1.38
BioCardia logo
BCDA
BioCardia
1.5$3.49flat$59.31 million$710,000.00-1.80
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.79flat$57.86 million$10,000.000.00
Organovo logo
ONVO
Organovo
0.7$7.64flat$57.43 million$2.20 million0.00News Coverage
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$2.08flat$56.45 million$200,000.00-0.87Decrease in Short Interest
Brickell Biotech logo
BBI
Brickell Biotech
1.5$0.82flat$56.23 million$7.92 million-0.34News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.16flat$52.32 millionN/A0.00Decrease in Short Interest
News Coverage
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.15flat$39.95 million$192.41 million0.75News Coverage
ENTX
Entera Bio
1.2$2.93flat$33.60 million$240,000.00-4.31
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$2.93flat$33.27 millionN/A-0.97Decrease in Short Interest
News Coverage
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$1.48flat$26.81 million$10,000.000.00News Coverage
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.35flat$22.49 million$3.61 million-0.31
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.